{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T03:08:07Z","timestamp":1779073687409,"version":"3.51.4"},"reference-count":20,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Olverembatinib is approved in China to treat patients with chronic\u2010 or accelerated\u2010phase chronic myeloid leukemia (CML\u2010CP or CML\u2010AP) with\n                    <jats:italic>T315I<\/jats:italic>\n                    mutations and CML\u2010CP that is resistant and\/or intolerant to first\u2010 and second\u2010generation tyrosine kinase inhibitors. The objective of this study was to determine the effects of a high\u2010fat meal on the pharmacokinetics of olverembatinib in patients with CML. Twelve participants were enrolled and received olverembatinib treatment over two periods, with a washout of 7\u2009days between consecutive doses. Pharmacokinetics and safety were assessed in all participants. When olverembatinib was administered with a high\u2010fat meal, the maximum plasma concentration (\n                    <jats:italic>C<\/jats:italic>\n                    <jats:sub>max<\/jats:sub>\n                    ) and area under the plasma concentration versus time curve from time 0 to infinity (AUC\n                    <jats:sub>0\u2013\u221e<\/jats:sub>\n                    ) of olverembatinib increased by 105.74% and 69.74%, respectively, compared to fasting conditions. The median time to maximum plasma concentration (\n                    <jats:italic>T<\/jats:italic>\n                    <jats:sub>max<\/jats:sub>\n                    ) of olverembatinib was not affected when it was administered with a high\u2010fat meal, and the geometric mean terminal plasma half\u2010life (\n                    <jats:italic>t<\/jats:italic>\n                    <jats:sub>1\/2<\/jats:sub>\n                    ) was comparable between high\u2010fat meal and preprandial conditions (26.8 vs. 31.1\u2009h). The safety profile of olverembatinib was consistent with observations from previous studies; all treatment\u2010related adverse events were mild, and no serious adverse event was reported. These results indicate that consumption of a high\u2010fat meal 30\u2009min before administering olverembatinib can increase its plasma exposure to some extent.\n                  <\/jats:p>","DOI":"10.1111\/cts.70545","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T16:54:03Z","timestamp":1778345643000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of a High\u2010Fat Meal on the Pharmacokinetics of Olverembatinib in Patients With Chronic Myeloid Leukemia"],"prefix":"10.1111","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3740-9056","authenticated-orcid":false,"given":"Hengbang","family":"Wang","sequence":"first","affiliation":[{"name":"Guangzhou Healthquest Pharma Co. Ltd.  Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4999-6975","authenticated-orcid":false,"given":"Yun","family":"Yang","sequence":"additional","affiliation":[{"name":"Guangzhou Healthquest Pharma Co. Ltd.  Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9586-2867","authenticated-orcid":false,"given":"Zi","family":"Chen","sequence":"additional","affiliation":[{"name":"Guangzhou Healthquest Pharma Co. Ltd.  Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7768-5249","authenticated-orcid":false,"given":"Min","family":"Yu","sequence":"additional","affiliation":[{"name":"Guangzhou Healthquest Pharma Co. Ltd.  Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8614-142X","authenticated-orcid":false,"given":"Lixin","family":"Jiang","sequence":"additional","affiliation":[{"name":"Ascentage Pharma Group Inc.  Rockville Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5530-7869","authenticated-orcid":false,"given":"Lichuang","family":"Men","sequence":"additional","affiliation":[{"name":"Guangzhou Healthquest Pharma Co. Ltd.  Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7634-7712","authenticated-orcid":false,"given":"Hua","family":"Yan","sequence":"additional","affiliation":[{"name":"Guangzhou Healthquest Pharma Co. Ltd.  Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6027-3604","authenticated-orcid":false,"given":"Dajun","family":"Yang","sequence":"additional","affiliation":[{"name":"Guangzhou Healthquest Pharma Co. Ltd.  Guangzhou China"},{"name":"Ascentage Pharma Group Inc.  Rockville Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1672-2262","authenticated-orcid":false,"given":"Yifan","family":"Zhai","sequence":"additional","affiliation":[{"name":"Guangzhou Healthquest Pharma Co. Ltd.  Guangzhou China"},{"name":"Ascentage Pharma Group Inc.  Rockville Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2022.58.11.3441854"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm301581y"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010022\u201001680\u20109"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19845"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70021"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088\u2010200544090\u201000001"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/978\u20103\u2010319\u201091439\u20108_2"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1312"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.2147\/PGPM.S32145"},{"key":"e_1_2_9_11_1","unstructured":"US Food and Drug Administration \u201cPrescribing Information for Bosulif (Bosutinib) \u201daccessed April 14 2026 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/203341lbl.pdf."},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12082"},{"key":"e_1_2_9_13_1","unstructured":"US Department of Health and Human Services FDA and CDER \u201cGuidance for Industry: Food\u2010Effect Bioavailability and Fed Bioequivalence Studies \u201daccessed April 15 2023 https:\/\/www.fda.gov\/media\/70945\/download."},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1021\/js960085v"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2017.01.014"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmpk.2023.100502"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2007.08.043"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280\u2010011\u20101688\u20107"},{"key":"e_1_2_9_19_1","unstructured":"US Food and Drug Administration \u201cClinical Pharmacology and Biopharmaceutics Review(s) of Bosutinib \u201daccessed April 15 2025 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203341Orig1s000ClinPharmR.pdf."},{"key":"e_1_2_9_20_1","unstructured":"US Food and Drug Administration \u201cPrescribing Information for Gleevec (Imatinib Mesylate) \u201daccessed April 14 2026 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/021588s024lbl.pdf."},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045\u2010022\u201001334\u2010z"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70545","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.70545","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70545","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T02:52:46Z","timestamp":1779072766000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.70545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1111\/cts.70545"],"URL":"https:\/\/doi.org\/10.1111\/cts.70545","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2025-11-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70545"}}